Results 241 to 250 of about 841,619 (362)

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

open access: yesMolecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu   +10 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

open access: yesMolecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor   +2 more
wiley   +1 more source

Mediators of interpersonal violence and drug addiction severity among methamphetamine users in Cape Town, South Africa

open access: green, 2014
Andréa L. Hobkirk   +5 more
openalex   +2 more sources

Targeting TNBC: core–shell polycationic polyurea dendrimers with inherent anticancer activity

open access: yesFEBS Open Bio, EarlyView.
Core–shell polycationic PURE dendrimers were tested in TNBC‐derived tumor models. Both formulations selectively targeted TNBC and effectively reduced tumor volume. PUREG4‐OEI48 suppressed tumor growth without detectable toxicity, whereas PUREG4‐OCEI24, despite showing efficacy, induced hepatic toxicity.
Adriana Cruz   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy